More than one in eight American men aged 25 to 49 face infertility, according to recent data from the U.S. Department of Health and Human Services. This issue is widespread, prompting significant investments in research. A biotech company from Utah, Paterna Biosciences, is making headlines this week by successfully growing mature sperm from stem cells in a lab, thanks to collaboration with the Mayo Clinic. They claim this breakthrough could help men who struggle to conceive.
Paterna has also tested this lab-grown sperm with promising results for creating embryos. Larry Lipshultz, a urologist from Baylor College, calls this development a significant leap in reproductive health. He noted they’ve identified crucial growth factors needed to develop mature sperm, something that had remained elusive until now.
Paterna’s co-founder, Alexander Pastuszak, highlights this work as the first major advancement since intracytoplasmic sperm injection was introduced over three decades ago. He explained that their research focused on the molecular programming involved in sperm production, leading them to create a reliable method to grow sperm in vitro.
Initially, they explored culturing human testicular cells to aid sperm development. However, they found that computational biology offered a more effective approach. By replicating essential molecular signals using specific growth mediums, they successfully directed stem cells to develop into mature sperm.
The initial experiments with lab-grown sperm included creating test embryos for safety validations. Future steps will involve more extensive research, particularly concerning stem cells from men who have infertility issues.
However, it’s important to note that Paterna’s findings are not yet peer-reviewed. In the past, other companies, like France’s Kallistem, claimed similar breakthroughs only to face scrutiny later. Nevertheless, Paterna has credibility, having received recognition in the MedTech Accelerator program, which is associated with the Mayo Clinic.
Despite the excitement, cost remains a concern. Paterna estimates their new procedure could range from $5,000 to $12,000, which is significantly less than traditional IVF costs that can reach $30,000. This pricing may still pose barriers for many men, as discussed by health policy researcher Maria Polyakova, who emphasized how insurance coverage affects accessibility to fertility treatments.
With advances like those from Paterna, the landscape of infertility treatment may be changing rapidly. Ongoing studies and policy discussions will shape how these innovations will be integrated into wider healthcare practices, ultimately influencing family planning decisions for many couples.
Source link
Biotechnology,male infertility,private equity,sperm
